59 related articles for article (PubMed ID: 20434555)
1. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.
Lambeck AJ; Nijman HW; Hoogeboom BN; Regts J; de Mare A; Wilschut J; Daemen T
Vaccine; 2010 Jun; 28(26):4275-82. PubMed ID: 20434555
[TBL] [Abstract][Full Text] [Related]
2. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
4. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
Walczak M; de Mare A; Riezebos-Brilman A; Regts J; Hoogeboom BN; Visser JT; Fiedler M; Jansen-Dürr P; van der Zee AG; Nijman HW; Wilschut J; Daemen T
Mol Pharm; 2011 Feb; 8(1):65-77. PubMed ID: 20825215
[TBL] [Abstract][Full Text] [Related]
5. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
6. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.
Huckriede A; Bungener L; Holtrop M; de Vries J; Waarts BL; Daemen T; Wilschut J
Vaccine; 2004 Mar; 22(9-10):1104-13. PubMed ID: 15003637
[TBL] [Abstract][Full Text] [Related]
8. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
9. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
10. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses.
Speidel K; Osen W; Faath S; Hilgert I; Obst R; Braspenning J; Momburg F; Hämmerling GJ; Rammensee HG
Eur J Immunol; 1997 Sep; 27(9):2391-9. PubMed ID: 9341785
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.
Riezebos-Brilman A; Regts J; Chen M; Wilschut J; Daemen T
Vaccine; 2009 Jan; 27(5):701-7. PubMed ID: 19041356
[TBL] [Abstract][Full Text] [Related]
12. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
[TBL] [Abstract][Full Text] [Related]
13. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
Lipford GB; Bauer S; Wagner H; Heeg K
Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
15. The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity.
de Mare A; Bungener LB; Regts J; de Vries-Idema J; van der Zee AG; Wilschut J; Daemen T
Vaccine; 2008 May; 26(19):2314-21. PubMed ID: 18400343
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
Herd KA; Harvey T; Khromykh AA; Tindle RW
Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
[TBL] [Abstract][Full Text] [Related]
17. Semliki forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity.
Tannis LL; Gauthier A; Evelegh C; Parsons R; Nyholt D; Khromykh A; Bramson JL
Vaccine; 2005 Jul; 23(33):4189-94. PubMed ID: 16005737
[TBL] [Abstract][Full Text] [Related]
18. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
19. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.
Vignuzzi M; Gerbaud S; van der Werf S; Escriou N
J Gen Virol; 2001 Jul; 82(Pt 7):1737-1747. PubMed ID: 11413386
[TBL] [Abstract][Full Text] [Related]
20. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
